Bausch + Lomb Corporation (BLCO) – What Are Researchers Saying About This Stock?

Bausch + Lomb Corporation (NYSE:BLCO) has been assigned an average recommendation of “Hold” from the fifteen brokerages that are covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, seven have assigned a hold recommendation, six have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $19.46.

Several equities analysts recently issued reports on BLCO shares. UBS Group assumed coverage on Bausch + Lomb in a research report on Thursday, July 30th. They set a “buy” rating and a $21.00 price target on the stock. Needham & Company LLC reiterated a “hold” rating on shares of Bausch + Lomb in a report on Tuesday, September 15th. HC Wainwright reissued a “buy” rating and set a $21.00 price target on shares of Bausch + Lomb in a research report on Friday, August 28th. Barclays upgraded shares of Bausch + Lomb to a “strong-buy” rating in a research report on Wednesday, October 7th. Finally, Evercore set a $17.00 price target on Bausch + Lomb in a report on Monday, July 6th.

Insider Activity at Bausch + Lomb

In other Bausch + Lomb news, CAO Frederick Munsch sold 52,900 shares of the business’s stock in a transaction on Monday, August 10th. The shares were sold at an average price of $16.78, for a total transaction of $887,662.00. Following the transaction, the chief accounting officer directly owned 45,831 shares of the company’s stock, valued at approximately $769,044.18. The trade was a 53.58% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Eschenbach Andrew C. Von sold 12,500 shares of the company’s stock in a transaction on Thursday, August 6th. The stock was sold at an average price of $16.50, for a total transaction of $206,250.00. Following the completion of the transaction, the director owned 69,792 shares of the company’s stock, valued at $1,151,568. This trade represents a 15.19% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 71,459 shares of company stock worth $1,194,370 over the last three months. Insiders own 1.45% of the company’s stock.

Hedge Funds Weigh In On Bausch + Lomb

Hedge funds and other institutional investors have recently modified their holdings of the stock. Beach Point Capital Management LP bought a new position in shares of Bausch + Lomb in the 3rd quarter worth approximately $5,882,000. Counterpoint Mutual Funds LLC purchased a new position in Bausch + Lomb during the third quarter valued at $670,000. Roxbury Financial LLC purchased a new position in Bausch + Lomb during the third quarter valued at $33,000. Engineers Gate Manager LP bought a new position in shares of Bausch + Lomb in the 2nd quarter worth about $1,479,000. Finally, Squarepoint Ops LLC increased its stake in shares of Bausch + Lomb by 31.7% in the 2nd quarter. Squarepoint Ops LLC now owns 24,379 shares of the company’s stock worth $404,000 after acquiring an additional 5,861 shares in the last quarter. Hedge funds and other institutional investors own 11.07% of the company’s stock.

Bausch + Lomb Stock Up 1.1%

Shares of BLCO opened at $17.12 on Friday. The firm has a market cap of $6.12 billion, a P/E ratio of -35.66, a P/E/G ratio of 0.53 and a beta of 0.56. The company has a debt-to-equity ratio of 0.79, a current ratio of 1.55 and a quick ratio of 1.02. Bausch + Lomb has a 1 year low of $14.44 and a 1 year high of $18.92. The stock has a 50 day simple moving average of $17.16 and a two-hundred day simple moving average of $16.47.

Bausch + Lomb (NYSE:BLCO) last announced its quarterly earnings data on Wednesday, July 29th. The company reported $0.15 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.16 by ($0.01). Bausch + Lomb had a negative net margin of 3.21% and a positive return on equity of 4.14%. The business had revenue of $1.39 billion during the quarter, compared to analysts’ expectations of $1.37 billion. During the same period last year, the company posted ($0.18) EPS. Bausch + Lomb’s revenue for the quarter was up 9.1% on a year-over-year basis. On average, analysts forecast that Bausch + Lomb will post 0.81 earnings per share for the current fiscal year.

About Bausch + Lomb

Bausch + Lomb Corporation (NYSE: BLCO) is a global eye-health company that develops, manufactures and markets products for vision care, ophthalmic pharmaceuticals and eye surgery. The company serves consumers, eye-care professionals, hospitals and surgical centers through a portfolio spanning contact lenses, contact-lens care products, prescription medicines, over-the-counter eye-care products and surgical equipment.

Its vision-care portfolio includes the Biotrue and INFUSE contact-lens brands, as well as solutions and other products used to clean and maintain contact lenses.